Bifidumbacterin forte in the treatment of acute viral hepatitis
https://doi.org/10.31146/1682-8658-ecg-227-7-18-23
Abstract
Relevance. In patients with acute viral hepatitis A and B, favorable conditions are created for the development of dysbacteriosis. As a result, the toxic load on the liver increases. For effective treatment of acute viral hepatitis A and B, it is necessary to examine for intestinal dysbiosis before and after treatment and subsequent correction of identified disorders. Aim. To study the clinical course, functional state of the liver, intestinal microflora in patients with acute viral hepatitis A and B and the effectiveness of using bifidumbacterin forte for the correction of intestinal microflora. Materials and methods. The work used clinical and laboratory data from 54 patients with acute viral hepatitis A and B. The main group of patients received bifidumbacterin forte against the background of basic therapy. Patients in the comparison group were on traditional therapy. Clinical, biochemical, bacteriological parameters were observed before the start of therapy and 15 days after its start, serological markers - upon admission. Results. During the therapy, in patients of the main group, the disappearance of intoxication, lethargy, weakness, pain, and normalization of liver size were observed earlier in comparison with the control group. Symptoms of pigment metabolism disorders disappeared significantly earlier: yellowness of the skin, itching of the skin, changes in the color of urine and feces. A dynamic study of liver tests demonstrated a more rapid reverse development of biochemical disorders of the functional state of the liver in patients who received bifidumbacterin forte as part of complex treatment. Conclusion. The use of bifidumbacterin forte in patients with acute viral hepatitis A and B against the background of basic treatment has a positive effect on some clinical manifestations, biochemical parameters, and individual components of the intestinal microflora.
About the Authors
L. G. Zhdanovich
Ryazan State Medical University
Russian Federation
Russian Federation
V. A. Martynov
Ryazan State Medical University
Russian Federation
Russian Federation
References
1. Asrani S. K., Devarbhavi H., Eaton J., Kamath P. S. Burden of liver diseases in the world. J. Hepatol. 2019; 70: 151-171. doi: 10.1016/j.jhep.2018.09.014.
2. Yu L. X., Schwabe R. F. The gut microbiome and liver cancer: Mechanisms and clinical translation. Nat. Rev. Gastroenterol. Hepatol. 2017; 14: 527-539. doi: 10.1038/nrgastro.2017.72.
3. Zhdanovich L. G., Martynov V. A. Probiotics and hepatoprotectors in the treatment of acute viral hepatitis. Experimental and Clinical Gastroenterology. 2022;(10):8-13. (In Russ.) doi: 10.31146/1682-8658-ecg-206-10-8-13.@@ Жданович Л. Г., Мартынов В. А. Пробиотики и гепатопротекторы в лечении острых вирусных гепатитов. Экспериментальная и клиническая гастроэнтерология. 2022;(10):8-13. doi: 10.31146/1682-8658-ecg-206-10-8-13.
4. Jiang L., Lang S., Duan Y., Zhang X. et al.Intestinal Virome in Patients With Alcoholic Hepatitis. Hepatol. 2020; 72: 2182-2196. doi: 10.1002/hep.31459.
5. Karaseva E. A., Martynov V. A., Zhdanovich L. G., Ageeva K. A. Dyspepsia syndrome and pathological changes of the upper gastrointestinal mucosa in patients with acute viral hepatitis A and B. Bulletin of Medical Science. 2019; 14 (2): 70-73. (In Russ.) doi: 10.31684/2541-8475.2019.2(14).70-73.@@ Карасева Е. А. Мартынов В.А, Жданович Л. Г., Агеева К. А. Синдром диспепсии и патологические изменения слизистой оболочки верхних отделов желудочно-кишечного тракта у больных острыми вирусными гепатитами А и В. Бюллетень медицинской науки. 2019; 2 (14): 70-73. doi: 10.31684/2541-8475.2019.2(14).70-73.
6. Schnabl B., Brenner D. A.Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014; 146: 1513-1524. doi: 10.1053/j.gastro.2014.01.020.
7. Libertucci J., Young V. B. The role of the microbiota in infectious diseases. Nat. Microbiol. 2019; 4: 35-45. doi: 10.1038/s41564-018-0278-4.
8. Floch M. H. Probiotics and functional foods in gastrointestinal disorders. Gastroenterol. Rep. 2001; 3(4): 343-350. doi: 10.1007/s11938-002-0054-6.
9. Pyatova L. G. Clinical efficacy of probiotics and hepatoprotectors in the complex treatment of acute viral hepatitis. I. P. Pavlov Russian Medical Biological Herald. 2008; 1: 45-49. (In Russ.)@@ Пятова Л. Г. Клиническая эффективность применения пробиотиков и гепатопротекторов в комплексном лечении острых вирусных гепатитов. Российский медико-биологический вестник им. академика И. П. Павлова. 2008; 1: 45-49.
10. Fraschini F. Pharmacology of Silymarin. Clin. Drug. Invest. 2002; 22 (1): 51-65. doi: 10.12691/jnh-2-3-1.
11. Su G., Ko C., Bercik P., Falck-Ytter Y. et al. AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders. Gastroenterology. 2020; 159 (2): 697-705. doi: 10.1053/j.gastro.2020.05.059.
12. Zeng Y., Chen S., Fu Y., Wu W. et al. Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. J. Viral Hepat. 2020; 27 (2): 143-155. doi: 10.1111/jvh.13216.
13. Jiang L., Lang S., Duan Y., Zhang X. et al.Intestinal Virome in Patients With Alcoholic Hepatitis. Hepatology. 2020; 72:2182-2196. doi: 10.1002/hep.31459.
14. Aly A.M., Adel A., El-Gendy A.O., Essam T. M. et al. Gut microbiome alterations in patients with stage 4 hepatitis C. Gut Pathog. 2016; 8: 42. doi: 10.1186/s13099-016-0124-2.
15. Sung C.M., Chen K. F., Lin Y. F., Ke H. M. et al. Predicting Clinical Outcomes of Cirrhosis Patients with Hepatic Encephalopathy from the Fecal Microbiome. Cmgh. 2019; 8: 301-318. doi: 10.1016/j.jcmgh.2019.04.008.
Review
For citations:
Zhdanovich L.G., Martynov V.A. Bifidumbacterin forte in the treatment of acute viral hepatitis. Experimental and Clinical Gastroenterology. 2024;(7):18-23. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-227-7-18-23
Views:
546
Email this article 